目的 可调节剂量(AMD)的治疗方案是近几年提出用于支气管哮喘(简称哮喘)维持治疗的一种新的措施.与传统的固定剂量(FD)的治疗方案有很大不同.也由此引发了很多争议.此实验比较了两种治疗方案可调节剂量布地奈德/福莫特罗干粉剂与固定剂量氟替卡松/沙美特罗吸入粉剂对慢性持续性哮喘患者的疗效.方法 68例哮喘患者随机分为AMD组与FD组.治疗24周后比较两组患者治疗前后的哮喘证状评分、哮喘发作次数、夜间憋醒次数、无症状天数、缓解症状所需时间以及PEF、FEV1%的变化.结果 最终59例患者完成实验.两组患者在临床症状及肺功能指标的改善等方面均相似.但是AMD组患者症状缓解时间较FD组患者更短(P<0.05).结论 两种治疗方法均能有效的控制哮喘,改善患者症状,但AMD的治疗方案能使患者获得更快的临床控制.%Objective Adjustable maintenance dosing(AMD) is recently recommended as a newmaintenance therapy for the majority of patients with persistent bronchial asthma(asthma). Because it isdifferent from fixed-dosing (FD) regimen, much controversy is aroused between these two differentstrategies. In this article, AMD with budesonide/formoterol compared with FD salmeterol/fluticasone inadults with persistent asthma. Methods Sixty-eight asthmatic patients were randomised to FD or AMD for24 weeks,asthma control questionnaire score, number of symptom-free days, number of asthmatic attack,number of days with nocturnal awakenings clue to asthma, spending time of improved symptom andpulmonary function were measured pre-and post-treatment. Results Fifty-nine patients finished thisexperiment,improvement of clinical symptom and pulmonary function was similar with AMD and FD, butspending time of improved symptom of AMD was shorter than that of FD(P<0.05). Conclusion Bothmethods could control asthmatic symptom, but AMD could improve symptom faster than FD.
展开▼
